Troponin I (TnI) is a muscle-speciWc protein and plays an allosteric function in the Ca 2+ regulation of cardiac and skeletal muscle contraction. Expression of cloned cDNA in Escherichia coli is an essential approach to preparing human TnI and mutants for structural and functional studies. The expression level of cardiac TnI in E. coli is very low. To reduce the potential toxicity of cardiac TnI to the host cell, we constructed a bi-cistronic expression vector to co-express cardiac TnI and cardiac/slow troponin C (TnC), a natural binding partner of TnI and a protein that readily expresses in E. coli at high levels. The co-expression moderately increased the expression of cardiac TnI although a high amount of TnC protein was produced from the bi-cistronic mRNA. The use of an E. coli strain containing additional tRNAs for certain low bacterial usage eukaryotic codons improved the expression of cardiac TnI. ModiWcations of two 5Ј-regional codons that have predicted low usages in bacterial cells did not reproduce the improvement, indicating that not the 5Ј but the overall codon usage restricts the translational eYciency of cardiac TnI mRNA in E. coli. However, deletion of the cardiac TnI-speciWc N-terminal 28 amino acids signiWcantly improved the protein expression independent of the host cell tRNA modiWcations. The results suggest that the regulatory N-terminal domain of cardiac TnI is a dominant factor for the incompatibility in bacterial cells, supporting its role in modulating the overall molecular conformation.
Muscle contraction is regulated by intracellular Ca
2+ via the thin Wlament-based troponin-tropomyosin system. Troponin is a striated muscle-speciWc protein complex contains three subunits: the Ca 2+ -binding subunit troponin C (TnC), 1 the tropomyosin binding subunit troponin T (TnT) and the inhibitory subunit troponin I (TnI) [1, 2] . During muscle contraction, cytoplasmic Ca 2+ rises and binds to TnC to induce a series of conformational changes in the troponin complex that release the inhibition of actomyosin ATPase and activate force development [3] . Three homologous TnI genes (cardiac, fast skeletal muscle, and slow skeletal muscle) have evolved in vertebrates to encode muscle-type-speciWc TnI isoforms [4] . Primary structures of cardiac, fast and slow skeletal muscle TnI isoforms are highly conserved. The main structural diVerence is a cardiac TnI-speciWc »30 amino acids N-terminal extension [5] .
Expression of cloned cDNA in bacteria is widely used in the preparation of TnI proteins for structural and functional studies. This approach is especially critical to the preparations of human TnI and site-speciWc mutations. A challenge here is the low expression level of cardiac TnI in Escherichia coli [6] . Although fusion protein expressions may increase the yield, TnI is an allosteric protein [3, 5] in which any fusion peptide may aVect its structure and function. To avoid the need of removing the fusion peptide after puriWcation, direct expression of non-fusion TnI protein is desirable for accurate structural and functional characterizations. In the present study, we investigated the factors that limit the expression of cardiac TnI in E. coli. To reduce the potential toxicity of cardiac TnI to the host cell, we constructed a bi-cistronic expression vector to co-express cardiac TnI and cardiac/slow TnC, a natural binding partner of TnI and a protein that readily expresses in E. coli at very high levels [7] . To examine the eVect of prokaryotic usage of eukaryotic codons on the translational eYciency of cardiac TnI mRNA, we compared expression in a host E. coli strain containing additional tRNAs for certain low bacterial usage eukaryotic codons with that in host bacteria containing only E. coli tRNAs. The co-expression with TnC only moderately increased the expression of cardiac TnI although a high amount of TnC protein was produced from the bi-cistronic mRNA. The use of tRNA-enhanced E. coli host to increase the usage of eukaryotic codons did improve the level of expression. To test whether the usage of codons near the 5Ј-end of the mRNA makes a major contribution to the restriction of cardiac TnI expression in bacterial cells [8, 9] , we modiWed two 5Ј codons that have predicted low usages in E. coli. However, the modiWcation of only 5Ј codons did not reproduce the beneWcial eVect of improving the overall codon usage. In contrast, deletion of the N-terminal 28 amino acids of cardiac TnI signiWcantly improved the protein expression in the absence of host tRNA modiWcation. The results suggest that the N-terminal region of cardiac TnI is a dominant factor for the incompatibility during bacterial expression. With the regulatory role of the N-terminal domain of cardiac TnI, the results support its function through modulating the overall molecular conformation.
Materials and methods

Reverse transcription-coupled polymerase chain reaction cloning of cDNAs encoding human cardiac TnI and human cardiac TnC
Two microgram of total RNA from adult human ventricular muscle was used as template for cloning of cDNAs encoding cardiac TnI and cardiac/slow TnC by reverse transcription-coupled polymerase chain reaction (RT-PCR). As described previously [10] , total Wrst strand human cardiac cDNA was synthesized using avian myeloblastosis virus reverse transcriptase with an oligo-dT primer. Using the cDNA as templates, PCR was carried out using two pairs of oligo nucleotide primers Xanking the coding regions of cardiac TnI and cardiac/slow TnC, respectively. For each pair, the upstream forward primer was synthesized according to the published sequence Xanking the translation initiation codon [11, 12] . The downstream reverse primer was designed as a complementary sequence to the region Xanking the translation termination codon. Double-stranded cDNAs encoding human cardiac TnI and human cardiac/slow TnC were obtained by 35 cycles of PCR using 90% Taq DNA polymerase and 10% Pfu DNA polymerase with proofreading activity (Stratagene) to reduce the rate of random mutations.
At restriction enzyme cloning sites constructed in the PCR primers, the human cardiac TnI cDNA was digested with NcoI and BamHI, puriWed by agarose gel electrophoresis, and recovered by the Prep-A-Gene glass beads-binding method (Bio-Rad Laboratories) according to the manufacturer's protocol. The cDNA insert was ligated to NcoI-BamHI-cut pET3d plasmid, a T7 RNA polymerase-based prokaryotic expression vector (Novagen). After transformation of JM109 E. coli cells, ampicillin-resistant colonies containing the recombinant plasmids were screened by PCR using T7 primer recognizing an upstream sequence in the pET3d vector [13] and the insert-speciWc reverse primer used in the cDNA ampliWcation. The cloned human cardiac TnI cDNA was conWrmed by dideoxy chain termination DNA sequencing at a service facility and transferred as an XbaI-BamHI fragment together with the upstream Shine-Dalgarno ribosome-binding sequence [14] to another T7 RNA polymerase-based expression vector pAED4 [15] .
The human cardiac/slow TnC cDNA ampliWed by PCR was Wrst cloned into the pCR4-TOPO vector using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA). Transformed bacterial colonies that were ampicillin-resistant and -galactosidase-negative were screened by PCR using T3 and T7 primers Xanking the cDNA insert to identify cDNA clones with the anticipated size. After conWrmation by DNA sequencing, the cloned human cardiac/slow TnC cDNA was isolated by restriction enzyme cleavage at the NcoI site built in the 5Ј cloning primer and an EcoRI site in the vector sequence, gel puriWed as above, and sub-cloned into NcoI-BamHI-cut pET3d expression plasmid for protein expression. This was done by Wrst ligating the compatible NcoI sites and then Wlling-in the 3Ј-non-compatible ends followed by Klenow DNA polymerase reaction followed by blunt-end ligation.
Construction of bi-cistronic expression vector
Together with TnI, TnC is one of the three subunits of muscle troponin complex and a protein naturally binds TnI with high aYnity [7] . Meantime, TnC is a eukaryotic protein that can readily express at very high levels in E. coli. To investigate whether co-expression of cardiac TnI and TnC would form binary protein complex in the host cell and reduce cardiac TnI's toxicity, we constructed a bi-cistronic expression vector to test the eVect on the level of protein expression. As illustrated in Fig. 1 , 50 ng of NcoI-BamHI-cut pET3d plasmid DNA was mixed with NcoI-EcoRI-cut human cardiac TnC cDNA and XbaI-BamHI-cut human cardiac TnI cDNA downstream of a Shan-Dalgarno ribosomal binding sequence from pET3d vector at 1:3:3 molar ratio in a 10 L reaction. After T4 DNA ligase treatment of the three fragments mixture at 16°C overnight to join the compatible sticky NcoI ends and BamHI ends, the reaction was diluted three times with double distilled water and Klenow DNA polymerase and dNTP substrates were added to Wll-in the EcoRI and XbaI ends. The reaction mixture was then boosted with T4 DNA ligase and reaction buVer and incubated at room temperature for 4 h for the second step blunt end ligation. The ligation products were used to transform competent JM109 E. coli and the ampecillin-resistant colonies were screened by PCR for the presence of both cardiac TnI and cardiac TnC cDNA inserts in tandem orientation downstream of the T7 promoter site (Fig. 1) . The recombinant plasmid was veriWed by restriction endonuclease mapping.
5Ј-codon modiWcations in human cardiac TnI cDNA
To investigate the possibility that low usages of the 5Ј codons [8, 9] of human cardiac TnI mRNA may hamper the expression in E. coli, we tested the eVect of 5Ј-regional codon modiWcations on the bacterial expression. PCR mutagenesis was carried out to replace two codons in the 5Ј-region of human cardiac TnI cDNA, which are predicted to have low usage in E. coli. As illustrated in Fig. 2 , an oligo nucleotide primer was synthesized to introduce base substitutions that convert codons Gly 4 and Arg 10 from GGG and AGG to GGU and CGU, respectively. On wild type human cardiac TnI cDNA template cloned in pET3d plasmid, 25 cycles of PCR was performed with the mutagenesis primer and T7 primer in the vector sequence to amplify a 118-bp DNA fragment. This DNA fragment containing the base modiWcations was puriWed by agarose gel and recovered by the Prep-A-Gene method as above. The double stranded DNA fragment was directly used as a megaprimer pairing with the downstream E8R reverse primer in a second PCR using wild type human cardiac TnI cDNA template to generate full-length human cardiac TnI cDNA containing the codon modiWcations. This biased PCR with low eYciency was performed for 30 cycles and yielded a detectable amount of full-length modiWed cardiac TnI cDNA. After gel puriWcation to remove the wild type cardiac TnI plasmid DNA, a third PCR of 25 cycles using T7 and E8R primers was carried out to further amplify the modiWed cardiac TnI cDNA. After restriction enzyme cuts at the 5Ј XbaI site and 3Ј EcoRI site, the cDNA was inserted into XbaI-EcoRI cut pAED4 vector. After transformation of JM109 E. coli, recombinant plasmid clone was screened by PCR and the codon-modiWed cDNA coding template was veriWed by DNA sequencing.
Prokaryotic expression plasmid encoding N-terminal truncated mouse cardiac TnI
To investigate whether the N-terminal region of the cardiac TnI polypeptide chain resulted in incompatibility in bacterial cells, we characterized the expression of an N-terminal truncated mouse cardiac TnI in which the N-terminal 28 amino acids are deleted [16] . The 5Ј-truncated mouse cardiac TnI cDNA cloned in pET3d plasmid was sequenced and veriWed by small-scale protein expression in E. coli [17] and Western blot identiWcation as described below.
Expression of human cardiac TnI in E. coli culture
The recombinant expression plasmids encoding wild type or modiWed cardiac TnI alone or bi-cistronically together with cardiac/slow TnC were used to transform chemically treated competent BL21(DE3)pLysS [13] or tRNA-modiWed BL21(DE3)CodonPlus-RP (Stratagene) E. coli cells using standard procedures. The transformed bacterial cells were selected on LB agar plates containing 100 g/ml ampicillin and 25 g/ml chloramphenical at 37°C overnight. The freshly transformed cells were cultured in 2£ tryptone-yeast broth containing 100 g/ml ampicillin and 12.5 g/ml chloramphenical at 37°C with vigorous shaking. Growth of the liquid culture was monitored by measuring O.D. 600 nm . The cultures were induced with 0.4 mM isopropyl-1-thiol--D-glactoside (IPTG) at various early-and mid-log phase growth time points. After three additional hours of culture at 37°C, the bacterial cells were harvested by centrifugation at 4°C and lyzed for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting analysis.
SDS-polyacrylamide gel electrophoresis and Western blotting
Transformed bacterial cells were lyzed in SDS-PAGE sample buVer containing 2% SDS, 1% -mercaptoethanol, 10% glycerol, 0.1% bromo- Fig. 1 . A bi-cistronic expression vector co-expressing cardiac TnC and cardiac TnI. The coding region of human cardiac TnC cDNA was isolated as an NcoI-EcoRI fragment from a recombinant pCR4-TOPO plasmid. The coding region of human cardiac TnI cDNA was isolated from a recombinant pET3d plasmid as an XbaI-BamHI fragment to include the upstream Shan-Dalgarno ribosome-binding sequence (S/D) [14] . By a two-step three-fragment-ligation procedure, the TnC and TnI cDNA inserts were cloned into NcoI-BamHI-cut pET3d plasmid to construct a bi-cistronic prokaryotic protein expression vector. Positions of the translation initiation and stop codons in the TnC and TnI cDNAs are indicated on the maps. 10, T7 promoter; T, transcription terminator. Fig. 2 . Codon modiWcations in human cardiac TnI cDNA. A mutagenesis primer was designed to change codons GGG (Gly 4 ) and AGG (Arg 10 ) in the human cardiac TnI cDNA into GGT and CGT, respectively, for higher usages in E. coli. The mutagenesis primer was synthesized as the complementary sequence of the cardiac TnI mRNA and paired with the T7 primer for PCR ampliWcation a 118-bp DNA fragment using wild type human cardiac TnI cDNA cloned in pET3d plasmid as template. This DNA fragment was gel puriWed and used as a megaprimer together with the E8R reverse primer in a second PCR on wild type human cardiac TnI cDNA template in pET3d plasmid to amplify the codon-modiWed fulllength cardiac TnI cDNA. The small amount of second PCR product was gel puriWed and further ampliWed by PCR using T7 and E8R primers. The third PCR product was modiWed at the XbaI and BamHI restriction sites, gel puriWed, and cloned into pAED4 expression plasmid. S/D, ShanDalgarno ribosome-binding sequence; T, transcription terminator.
phenol blue and 50 mM Tris-HCl, pH 8.8, by heating at 80°C for 5 min. Bacterial genomic DNA was sheared by passing through a 23G needle 10 times. The total protein extracts were clariWed by room temperature centrifugation at top speed in a microcentrifuge and resolved by 12% Laemmli SDS-gel with an acrylamide:bisacrylamide ratio of 45:1. Bovine cardiac TnI puriWed from ventricular muscle [10] and mouse cardiac/slow TnC puriWed from bacterial culture [10] were used as controls. The resulting gels were stained with Coomassie brilliant blue R250 to reveal the resolved protein bands and duplicate gels were electrically blotted to nitrocellulose membranes as previously described [18] . After blocking in 1% bovine serum albumin, the nitrocellulose membranes were incubated with an anticardiac TnI monoclonal antibody (mAb) TnI-1 [19] at 4°C overnight. The membranes were then repetitively washed under high stringency using Tris-buVered saline containing 0.5% Triton X-100 and 0.05% SDS, incubated with alkaline phosphatase-labeled anti-mouse IgG second antibody (Sigma Chemical Co.) at room temperature for 1 h, washed again as above, and developed in 5-bromo-4-chloro-3-indolylphosphate/nitro blue tetrazolium substrate solution as previously described [18] .
Data analysis
DNA and protein sequence analysis was done using the DNAStar computer program. Two-dimensional densitometry of SDS-gel and Western blot was carried out using the NIH Image program version 1.61. Statistical analysis was done by Student's t test.
Results and discussion
The higher copy number pAED4 vector gives a higher expression of cardiac TnI than that of pET3d Fig. 3a demonstrates the speciWc detection of cardiac TnI and cardiac/slow TnC expressed in E. coli culture by SDS-PAGE and TnI-1 mAb Western blotting. Under standard culture and induction conditions, only a low level of human cardiac TnI protein was detected in transformed BL21(DE3)pLysS culture by Western blotting using the TnI-1 mAb (Fig. 3b) . Between the low level expressions, pAED4 vector produced a higher expression than that of pET3d vector (Fig. 3b and Table 1 ). We have observed by the yields of plasmid DNA preparation from parallel transformed bacterial cultures as well as by agarose gel direct quantiWcation of the plasmid DNA extracted from bacterial cells (as normalized by the level of ribosomal RNAs) that pAED4 plasmid produces a copy number in the transformed E. coli cell approximately twice as that of pET3d (data not shown). Therefore, the higher level of cardiac TnI expression by pAED4 vector suggests an advantage of using high copy number expression vectors, especially for the production of hard-to-express proteins in E. coli culture.
Bi-cistronic co-expression with TnC improves the expression level of cardiac TnI
One hypothesis that we tested was that free cardiac TnI protein might be toxic to the host bacterial cell. Considering that TnC naturally binds TnI with high aYnity [6] and is a protein that readily expresses in E. coli at high levels, we examined whether co-expression of cardiac TnI with TnC would allow the formation of TnI-TnC binary protein complex in the bacterial cell and reduce the amount of free cardiac TnI to prevent the potential toxicity. To ensure coexpression in all transformed bacterial cells, we constructed a bi-cistronic expression vector encoding human cardiac TnI and human cardiac/slow TnC in a single mRNA (Fig. 1) . When the bi-cistronic expression plasmid was used to transform BL21(DE3)pLysS E. coli, co-expression of cardiac TnI and cardiac/slow TnC was achieved upon IPTG induction (Fig. 3c) . The co-expression with TnC had a beneWcial eVect on the expression level of cardiac TnI (Fig. 3c and Table 1 ), supporting the hypothesis that the presence of TnC could reduce the incompatibility of cardiac TnI with the host E. coli cell.
Similar to that seen in previous studies [20] [21] [22] , the improvement of cardiac TnI expression by using the TnCTnI bi-cistronic vector was moderate ( Table 1 ). The high level expression of TnC indicates the presence of an abundant amount of the bi-cistronic mRNA in the bacterial cell and the co-expression with cardiac TnI did not aVect the translational eYciency and accumulation of human cardiac TnC protein in E. coli. Same as that upstream of the cardiac TnC cDNA, the Shan-Dalgarno sequence upstream of the cardiac TnI cDNA was from pET3d vector. Accordingly, the translations of TnC and TnI cistrons were directed by identical ribosomal binding sites which should allow similar levels of translational initiation. Therefore, the signiWcantly lower level of cardiac TnI protein expression comparing to that of TnC suggests that the formation of binary TnI-TnC complex in the bacterial cell, although conveyed the moderate protective eVect, is of low eYciency. The chemical environment in bacterial cells is apparently diVerent from that of the muscle cells and may not be suitable for high aYnity binding between TnC and TnI. On the other hand, native troponin complex is known to resist to high salt buVers [23] . Therefore, the ineVective binding between TnI and TnC in bacterial cells might not be simply due to the solution environment but result from ineVective folding of the bacterially made troponin proteins (most likely cardiac TnI since the TnC protein was in excess and only a small portion needed to be correctly folded to saturate the co-expressed cardiac TnI). It has been demonstrated by us and many other laboratories that TnI and TnC puriWed from bacterial expression both have biochemical activities and can form functional TnI-TnC binary complex and tertiary troponin complex [3, 7, 10] . These results indicate that denaturing (urea buVer) and renaturing (Wnal dialysis) steps during the puriWcation of bacterial made TnI are necessary for the yield of biologically active proteins.
EVect of improving overall codon usage on the expression of human cardiac TnI in E. coli
The low versus high expressions of cardiac TnI and TnC proteins from a bi-cistronic mRNA indicates a posttranscriptional restriction of cardiac TnI expression. As discussed above, identical Shan-Dalgarno ribosomal binding sequences were used for the two translational units for similar eYciency in translational initiation. Therefore, the eVect of translational eYciency of human cardiac TnI mRNA on its expression in E. coli needs to be considered. It is well established that certain codons (AGG, AGA, CUA, AUA, CGA or CCC) that are frequently used in eukaryotic mRNA have low usages in prokaryotic cells and they may hinder the expression of eukaryotic proteins in E. coli [24] . To investigate whether improving the overall usage of human cardiac TnI codons in the host E. coli cell would improve the protein expression, we compared the use of regular BL21(DE3)pLysS cell containing only E. coli tRNAs and BL21 CodonPlus(DE3)-RP cell (Stratasgene) that has been genetically modiWed by the addition of tRNAs recognizing eukaryotic codons AGA, AGG, and CCC. The results in Fig. 3d and Table 1 show that human Table 1. cardiac TnI was expressed at higher levels in BL21 CodonPlus(DE3)-RP cells than that in BL21(DE3)pLysS cells. This observation supports the notion that low usage of these codons in the human cardiac TnI mRNA may be a limiting factor during protein expression in E. coli.
Similar to the expression of cardiac TnI alone, the use of tRNA-enhanced E. coli host cell also produced better expression by the bi-cistronic vector than that of using BL21(DE3)pLysS cell ( Fig. 3d and Table 1 ). This observation suggests that in the presence of TnC that may moderately reduce the toxic eVect of cardiac TnI, the initial production of cardiac TnI protein remains a dominant limiting factor during bacterial expression.
ModiWcation of the 5Ј-regional codons did not reproduce the beneWcial eVect of tRNA enhancement on cardiac TnI expression
It has been demonstrated that codon usage in the very 5Ј-region of the mRNA [8, 9] may be critical to the optimal expression of eukaryotic proteins in E. coli. There are two codons (Gly 4 , GGG and Arg 10 , AGG) in the 5Ј-region of human cardiac TnI mRNA that are predicted to have low usage in bacterial cells and may have contributed to the codon usage limitation to the protein expression. To investigate this hypothesis, we replaced these two codons in cloned human cardiac TnI cDNA with ones frequently used in E. coli [24] (Fig. 2) . Although a previous study saw improved expression of human cardiac TnI in E. coli by modifying codons Ala 2 and Gly 4 [25] , our modiWcation of Gly 4 and Arg 10 codons did not reproduce the improvement in cardiac TnI expression as that seen in the tRNAenhanced E. coli cells (Fig. 3e and Table 1 ). The results indicate that although overall codon usage is an important factor in the expression eYciency of cardiac TnI in E. coli (Fig. 3d) , the 5Ј-regional codon usage alone does not have a determining role.
SigniWcantly increased expression of cardiac TnI after deleting the N-terminal 28 amino acids
We previously observed that the core structure of turkey cardiac TnI without the N-terminal segment expressed in E. coli at a much higher level than that of intact turkey cardiac TnI [6] . Such improvement was also seen by others [25] . To quantitatively investigate the incompatibility eVects of cardiac TnI N-terminal region on bacterial expression, we studied the expression of an N-terminal truncated mouse cardiac TnI lacking amino acids 1-28. The results in Fig. 3f and Table 1 demonstrated that deletion of the N-terminal 28 amino acids of mouse cardiac TnI signiWcantly improved the level of protein expression in E. coli. This eVect was much larger than that by using the codonenhanced E. coli host cell ( Table 1 ). The use of codonenhanced host cell did not further improve the expression level of N-terminal truncated cardiac TnI (Fig. 3f and Table 1 ).
The expression of N-terminal truncated cardiac TnI involves alterations in both the mRNA and the protein produced. It has been observed that the mRNA structure may aVect bacterial expression of eukaryotic proteins [26] . The 5Ј-structure may aVect the stability of the mRNA and reduce the level of protein expression. However, the very high level TnC synthesized from the bi-cistronic mRNA indicates a signiWcant amount of the mRNA (Fig. 3) and precludes the role of mRNA instability in causing the low level bacterial expression of intact cardiac TnI.
The N-terminal segment of cardiac TnI polypeptide is a unique structure that is not present in fast or slow skeletal muscle TnI and may be proteolytically removed in the cardiac muscle during physiological adaptations [23] . The signiWcantly improved expression of N-terminal truncated cardiac TnI in E. coli suggests that the N-terminal segment has a negative eVect on bacterial expression. Deletion of this segment (Fig. 4) does not disrupt the core structure of Table 1 Expression of cardiac TnI in E. coli under diVerent conditions
The levels of cardiac TnC expression were determined by two-dimensional densitometry of Coomassie brilliant blue R250 stained SDS-PAGE gels as percentage of the total protein extracted from the bacterial cells (Fig. 3) . The levels of cardiac TnI expression were determined by two-dimensional densitometry of TnI-1 mAb Western blots (Fig. 3) and normalized by the levels of total protein and/or TnC determined densitometrically from parallel SDS-gels (n D 3-5). The expression levels of wild type codon intact cardiac TnI using pET3d vector in BL21(DE3)pLysS cell were used as the baseline (1.00) for comparisons. The values are shown as means § standard error.
a P < 0.01 when compared with the baseline value (indicated by ¤ ). b P < 0.01 when compared with the same constructs in BL21(DE3)pLysS cell. c P < 0.01 when compared with the intact cardiac TnI expressions. TnI [6, 23] and does not alter the overall positive charge of the protein (the isoelectric points of intact and N-terminal truncated mouse cardiac TnI are 9.57 and 9.59, respectively). Therefore, the possible mechanisms may include its direct toxicity to the host metabolism and/or its eVects on the stability and accumulation of the exogenous protein synthesized.
It is worth noting that the N-terminal domain of cardiac TnI contains the protein kinase A phosphorylation site (Ser 23 /Ser 24 in the mouse sequence, Fig. 4 ) that is a crucial site for physiological regulation of cardiac thin Wlament function [5] . Absent in skeletal muscle TnI, this region does not contain any known binding sites for other myoWlament proteins [3] . Deletion of this segment from cardiac TnI resulted in dominant eVects on cardiac muscle function in transgenic mice [16] . Therefore, the N-terminal segment of cardiac TnI may serve as a conformational modulator for the core structure and this conformational eVect may also be a mechanism for the incompatibility of intact cardiac TnI in bacterial cells.
EVects of early and late inductions on the expression of intact cardiac TnI
The incompatibility of the N-terminal peptide of cardiac TnI in the host bacteria may reduce the proportion of the positively transformed cells as a decreased growth rate was observed in E. coli cultures after IPTG induction of intact cardiac TnI expression (Fig. 5) . Due to the negative selection pressure from the N-terminal segment of cardiac TnI on the host bacteria, even a very low level leaked expression of intact cardiac TnI may rapidly reduce the positive cell population during culture. Consistently, we have found that the use of freshly transformed bacteria is critical to a successful preparative expression (data not shown). Starting from a predominantly positive cell population, the induction of cardiac TnI expression at a proper time point during the course of culture is also critical to the level of protein expression. Earlier induction would ensure that most cells in the culture are still positive. However, since a restricted duration of induction is also crucial to avoid the over growth of negative cells, earlier induction would yield less cells harvested per unit volume of the culture and lower the total yield of protein. To establish proper induction conditions for a maximum yield, we examined the induction of intact cardiac TnI expression at a series of cell densities. The results in Fig. 5 showed that when intact cardiac TnI was expressed alone, the expression level was decreased when induced at O.D. 600 nm > 0.3. Co-expression of cardiac TnI with TnC produced higher levels of expression at higher cell densities with the optimal induction O.D. 600 nm of 0.4.
In summary, diYculties in bacterial expression of cardiac TnI represent a challenging but intriguing model system for understanding the compatibility of eukaryotic proteins to the bacterial host during preparative expression. The present study demonstrates that removal of an incompatible submolecular structure of a foreign protein may overcome the low codon usage limitation that universally exists during bacterial expression of eukaryotic proteins. The Wnding that the N-terminal domain of cardiac TnI is a dominant factor for the incompatibility in bacterial cells supports its role in modulating the global conformation.
